← All trials
NCT05178810
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2021
- Primary completion
- Jun 20, 2024
- Completion date
- Jun 20, 2024
- First posted
- Jan 5, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ferrer Internacional S.A.Lead sponsor
- Utrecht UniversityCollaborator
- Stichting TRICALS FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.